According to a new report published by Allied Market Research, titled, “U.S. Cardiac Resynchronization Therapy Market, by Type, Application, and End User: Opportunity Analysis and Industry Forecast, 2020–2027,” the U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027.
Cardiac resynchronization therapy (CRT) also known as biventricular pacing or multisite ventricular pacing, is a type of treatment to help correct serious heart rhythm problems. It involves simultaneous pacing of the right ventricle (RV) and the left ventricle (LV). CRT devices assist heart beat efficiently and monitor heart condition, thereby the healthcare professional can provide proper treatment to the patient. Cardiac resynchronization therapy helps in restoring mechanical synchrony by electrically activating the heart in a synchronized manner.
Growth in aging population, rise in sedentary lifestyle along with surge in prevalence of cardiovascular diseases (CVDs), increase in technological developments in the CRT pacemakers and CRT defibrillators, the presence of advanced healthcare infrastructure, and surge in healthcare expenditure in the U.S. are expected to drive the market growth during the forecast period. For instance, in 2016, first, as well as second-generation products of the CRT market were available. In addition, the third-generation products is underway and Medtronic plc has become a pioneer in the CRT market by receiving a United States Food and Drug Administration (USFDA) approval for two MRI-Safe CRT-D devices in 2016. The third-generation products will facilitate MRI testing of patients implanted with CRT devices without incurring any complications or fatalities in the near future. However, high cost of CRT therapy and the presence of rigorous regulations for CRT devices in the U.S. are anticipated to hinder the market growth during the forecast period.
The U.S. cardiac resynchronization therapy market is segmented into type, application, and end user. By type, the market is categorized into CRT pacemaker and CRT defibrillator. The CRT defibrillator segment dominated the market in 2019, and is expected to continue this trend over the forecast period owing to an increase in adoption of CRT defibrillators over CRT pacemakers as well as the launch of technologically advanced CRT defibrillators.
By application, the U.S. cardiac resynchronization therapy market is classified into intraventricular dyssynchrony, interventricular dyssynchrony, and atrioventricular dyssynchrony. Intraventricular dyssynchrony is the principal factor responsible for contractile dysfunction, the one most affected by and most predictive of response to resynchronization therapy. According to a study published in the National Center for Biotechnology Information (NCBI), the incidence of Intraventricular dyssynchrony was high among patients presenting with left bundle branch block. Thereby, supporting the dominance of the intraventricular dyssynchrony segment in 2019 in terms of revenue.
By end user, the U.S. cardiac resynchronization therapy market is segregated into hospitals, ambulatory surgical centers, and specialized cardiac treatment centers. The hospitals segment is anticipated to lead the market during the assessment period as hospitals are the primary point for diagnosis and treatment of cardiovascular diseases.
Market participants are implementing growth strategies, namely, new product launches, mergers and acquisitions (M&As), and partnerships and collaborations to gain a competitive advantage. For instance, in February 2017, Boston Scientific Corporation launched the RESONATE cardiac resynchronization therapy defibrillator systems in Europe, featuring SmartCRT technology, indicated for heart failure patients across Europe.
The key players functioning in the U.S. cardiac resynchronization therapy market are Medtronic plc, Abbott Laboratories, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Lepu Medical Technology (Beijing) Co., Ltd., LivaNova PLC, MEDICO S.p.A., MicroPort Scientific Corporation, OSCOR Inc., and Osypka Medical GmbH.
Key Findings Of The Study
- On the basis of type, the CRT defibrillator segment was the highest contributor to the U.S. cardiac resynchronization therapy market in 2019
- On the basis of application, the intraventricular dyssynchrony segment dominated the U.S. cardiac resynchronization therapy market in 2019, and is expected to continue this trend during the forecast period.
- On the basis of end user, the specialized cardiac treatment centers segment is anticipated to register fastest CAGR during the forecast period